🏥 Abbott Labs (ABT) Trade Alert
Positioning in this healthcare giant as it breaks out from consolidation - here's the strategic play:
📌 Trade Levels
▶ Entry: $133.12 (confirmed above SMA 50)
🎯 Target: $147.21 (+10.6%)
🛑 Stop Loss: $126.00 (-5.3% risk)
⚖️ Risk/Reward: 1:2
Why ABT Now?
✅ Fundamental Strength:
Net Income Growth: "Strong growth" (+134% YoY in last report)
Dividend Aristocrat: 50+ years of dividend growth (current yield 1.9%)
Debt Health: Score 10/10 (Debt/Equity 0.26, Interest Coverage 15x)
✅ Technical Triggers:
Bullish crossover (50D > 200D MA)
RSI 55 - neutral with room to run
Volume surge on $132 breakout
Measured move target aligns with $147 zone
📊 Trade Management:
Entry: $133.12 (market price)
Scale In: Add at $130 if tested
Adjust Stop: Move to breakeven at $136
Partial Profit: Take 50% at $140
⚠️ Key Risks:
Sector rotation out of healthcare
FDA delays on new devices
Strong resistance at $138 (prior highs)
ABT dominates 4 growth segments:
Medical Devices (44% revenue)
Diagnostics (32%)
Nutrition (12%)
Generics (12%)
Recent FDA approval for Freestyle Libre 3 drives upside.
Trade active until next earnings (Oct 18). Let me know your take! 👇
#HealthcareStocks #DividendInvesting #BreakoutTrade
Positioning in this healthcare giant as it breaks out from consolidation - here's the strategic play:
📌 Trade Levels
▶ Entry: $133.12 (confirmed above SMA 50)
🎯 Target: $147.21 (+10.6%)
🛑 Stop Loss: $126.00 (-5.3% risk)
⚖️ Risk/Reward: 1:2
Why ABT Now?
✅ Fundamental Strength:
Net Income Growth: "Strong growth" (+134% YoY in last report)
Dividend Aristocrat: 50+ years of dividend growth (current yield 1.9%)
Debt Health: Score 10/10 (Debt/Equity 0.26, Interest Coverage 15x)
✅ Technical Triggers:
Bullish crossover (50D > 200D MA)
RSI 55 - neutral with room to run
Volume surge on $132 breakout
Measured move target aligns with $147 zone
📊 Trade Management:
Entry: $133.12 (market price)
Scale In: Add at $130 if tested
Adjust Stop: Move to breakeven at $136
Partial Profit: Take 50% at $140
⚠️ Key Risks:
Sector rotation out of healthcare
FDA delays on new devices
Strong resistance at $138 (prior highs)
ABT dominates 4 growth segments:
Medical Devices (44% revenue)
Diagnostics (32%)
Nutrition (12%)
Generics (12%)
Recent FDA approval for Freestyle Libre 3 drives upside.
Trade active until next earnings (Oct 18). Let me know your take! 👇
#HealthcareStocks #DividendInvesting #BreakoutTrade
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.